Physician profile
Daniel Rosenbaum
NPI 1073515706
$11,722.61
in general payments reported to CMS, 2019-2025
50 companies · $5,873 in 2025
The $5,873 reported for 2025 was more than what 88% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,420 · 2020: $302 · 2021: $326 · 2022: $933 · 2023: $1,233 · 2024: $1,636 · 2025: $5,873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,200 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,492 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,199.59 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,492.00 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $4,113.83 | 2019-2025 | |
| Abbott Laboratories | $1,048.04 | 2019-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Novo Nordisk INC | $992.42 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $541.01 | 2019-2025 | Tepezza, Evenity, Repatha |
| Insulet Corporation | $485.57 | 2019-2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $407.02 | 2021-2025 | |
| Lilly USA, LLC | $289.85 | 2019-2025 | Mounjaro, Zepbound |
| Dexcom, INC. | $272.00 | 2019-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $263.26 | 2019-2025 | Botox |
| Horizon Therapeutics Plc | $244.52 | 2021-2023 | Tepezza |
| Ascendis Pharma Endocrinology INC | $207.45 | 2023-2025 | Yorvipath |
| Valeritas, INC. | $182.50 | 2019 | |
| Corcept Therapeutics | $177.06 | 2022-2025 | Korlym |
| Astrazeneca Pharmaceuticals Lp | $172.71 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $166.73 | 2019-2025 | Verquvo, Steglatro, Steglujan |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $161.44 | 2022-2025 | Minimed 780g |
| Alexion Pharmaceuticals, INC. | $145.30 | 2022-2025 | Strensiq |
| Cequr Corporation | $133.07 | 2023-2025 | Cequr Simplicity |
| Beta Bionics, INC. | $125.49 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Exelixis INC. | $118.01 | 2022 | |
| Xeris Pharmaceuticals, INC. | $116.61 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Antares Pharma, INC. | $116.52 | 2021-2025 | Xyosted |
| Janssen Pharmaceuticals, INC | $107.28 | 2019-2024 | Xarelto |
| Madrigal Pharmaceuticals | $106.30 | 2025 | Rezdiffra |
| Vertiflex, INC. | $99.99 | 2019 | |
| Mannkind Corporation | $97.12 | 2023-2025 | Afrezza |
| Janssen Biotech, INC. | $89.52 | 2024-2025 | Tremfya, Simponi, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $75.84 | 2024-2025 | Entyvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.06 | 2019-2024 | Jardiance |
| Becton, Dickinson and Company | $58.15 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $56.92 | 2023-2024 | |
| Sequel Med Tech, LLC | $48.94 | 2025 | Twiist |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.67 | 2019-2020 | |
| W. L. Gore & Associates, INC. | $35.44 | 2022 | |
| Amryt Pharma Holdings Ltd | $32.21 | 2023 | Mycapssa |
| Ibsa Pharma INC. | $31.84 | 2022-2024 | Tirosint, Licart, Flector |
| Amneal Pharmaceuticals LLC | $29.45 | 2021-2023 | Unithroid |
| Senseonics, Incorporated | $29.00 | 2019 | |
| Companion Medical, INC. | $27.25 | 2019 | |
| Verity Pharmaceuticals INC. | $26.63 | 2024 | Tlando |
| Shire North American Group INC | $25.32 | 2019 | |
| Neurocrine Biosciences, INC. | $22.73 | 2025 | |
| Rgh Enterprises LLC | $22.46 | 2025 | |
| Halozyme INC | $22.19 | 2023 | |
| Embecta Corp. | $18.65 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Ardelyx, INC. | $16.92 | 2024 | Ibsrela |
| Rhythm Pharmaceuticals, INC. | $15.38 | 2024 | Imcivree |
| Phathom Pharmaceuticals, INC. | $15.26 | 2025 | Voquezna |
| Genzyme Corporation | $14.99 | 2023 | |
| Shionogi INC | $11.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Rosenbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.